July 26th 2024
The gene therapy giroctocogene fitelparvovec demonstrated superiority compared with the standard of care, routine prophylaxis, in hemophilia A treatment.
ASH Annual Meeting Coverage: Highlighting the Recent Updates in TKI Use in the Treatment of CML – Insights and Application for Managed Care
Keeping Pace With New Developments in Multiple Myeloma: Updates and Strategies to Optimize Bispecific Antibodies and CAR T-Cell Therapy
Addressing the Gaps and Clinical Challenges in Chronic Lymphocytic Leukemia: Updates and Strategies for Managed Care
NSAIDs May Be Safe for Use in Hemophilia, but More Research Is Needed